ANCEF
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 31m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANCEF is a cephalosporin antibiotic approved in 1973, administered via injection for bacterial infections. The drug is a first-generation cephalosporin used primarily for surgical prophylaxis and treatment of susceptible gram-positive and gram-negative infections. It functions by inhibiting bacterial cell wall synthesis.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating team focus on cost management and market defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ANCEF offers career experience in mature product management, managed-care negotiations, and hospital formulary strategy within a stable, established market. This role suits professionals seeking hands-on commercial execution and cost-optimization expertise rather than launch or innovation experience.
Senior Brand Manager (Specialty/Hospital)Medical Science Liaison
Worked on ANCEF at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.